OGMBT Banner AM20 940x285 Online2

Overview

 

News

The presenters for LST#4 have been notified of their presentation status.

Upcoming Abstract Submission Deadlines

LST#5:Microbiome Innovations  -  November 2, 2020

LST#7: New biologics, novel analytical tools - November 12, 2020

LST#8: Infection and Immunity - November 26, 2020

Downloads

Download the CONFERENCE GUIDE PDF

The life science tuesday guide booklets can be found below the life science tuesdays teasers

WELCOME TO OUR VIRTUAL MEETING ROOM

Our Annual Meeting is the melting pot of the Austrian Life Science Community - a place to listen to renowned speakers, for participants to present their latest work and for all of us to network in a family-like atmosphere. This year, we will meet in a virtual room via Zoom!

The layout in our virtual meeting room will enable interactivity in order to keep up the cherished spirit of learning from each other, exchanging ideas and giving each participant ample opportunities to discuss her/his research with colleagues, friends and senior scientists. Here is a sneak preview of what we envisage:

From September 21-23 our virtual meeting room will stage the Kick off event (2 sessions/day à 2h). You will hear lectures from renowned Plenary Speakers, our Austrian Life Science Awards Austria 2020 winners and get insights into the latest Corona research conducted in Austria. We will feature the Life Science Career Fair and will hear and discuss about cryo-EM and healthy ageing in the 21st Century, as Graz special contribution. Our much appreciated exhibition will be an interactive VirtualExpo (with live chat and live video calls), which will accompany us starting from the kick-off event on throughout the period of all Life Science Tuesdays.

Following the Kick off event, our virtual meeting room will open its’ doors for bi-weekly Life Science Tuesdays, where we will spend an afternoon together focussing and interacting on a specific topic – centrepieces will be invited talks, short talks, “Science Flashes” in lieu of posters, workshops/webinars and the VirtualExpo. One batch of Life Science Tuesdays will be held from October to December 2020 and a second batch from January to March 2021. For details on Life Science Tuesdays – read further

We as organisers strive to provide you as presenter, participant or exhibitor with the same scientific quality and interactivity as you are used to from previous ÖGMBT Annual Meetings!

Stay tuned for further information as we roll out our program step by step!

Your Organizing Committee,
Harald (Chair), Helmut & Alexandra

 

 

Life Science Tuesday Topics

 OGMBT LST Titel 1920x1080px v1 AK FINAL

 

Invited Speakers







Stéphane Guillouet
12 GUILLOUET round

INSA, FR




Marlene Oeffinger2 Oeffinger
Institut de recherches cliniques de Montréal (IRCM), CA






Jillian Petersen 5 petersen

University of Vienna, AT







Karin SchauppKarin Schaupp

Intern. Innovation and Business Consulting, Kainbach bei Graz, AT






Christoph Steininger SteiningerChristian

Medical University Vienna, AT

 

Organizing Committee

Harald Pichler (Chair)
Graz University of Technology

Helmut Bergler
University of Graz

Alexandra Khassidov
ÖGMBT

 

 

Scientific Committee

Christian Becker
University of Vienna

Gabriele Berg
Graz University of Technology

Michael Bergmann
Medical University of Vienna

Rolf Breinbauer
Graz University of Technology

Kristina Djinovic-Carugo
University of Vienna

Anita Emmerstorfer-Augustin
Graz University of Technology

Sebastian Falk
University of Vienna

Julia Feichtinger
Medical University of Graz

Kai Uwe Fröhlich
University of Graz

Klaus Graumann
Phoenestra GmbH

Giovanni Grillari
University of Natural Resources and Life Sciences

Gerald Höfler
Medical University of Graz

Elif Karagöz
University of Vienna

Cornelia Kasper
University of Natural Resources and Life Sciences           

Sabine Kienesberger
University of Graz

Georg Klima
Boehringer Ingelheim RCV GmbH & Co KG

Robert Kourist
Graz University of Technology

Tobias Madl
Medical Universty of Graz

Christine Moissl-Eichinger
Medical Universty of Graz

Bernd Nidetzky
Graz University of Technology  

Brigitte Pertschy
University of Graz

Tea Pavkov-Keller
University of Graz

Thomas Rattei
University of Vienna

Beate Rinner
Medical Universty of Graz

Gernot Schabbauer
Medical University of Vienna

Martina Schweiger
University of Graz

Stefan Schild
University of Graz

David Teis
Medical University of Innsbruck

 

VirtualExpo and Exhibitor Quiz

Our much-appreciated exhibition will be an interactive VirtualExpo, which will accompany us starting from the Kick off event and throughout the period of all Life Science Tuesdays.

We are convinced that the VirtualExpo with the challenging Exhibitor Quiz will be an interesting and fun place to be. The interactive tools embedded in the VirtualExpo – text chat and video call - will facilitate a personal conversation between participants and exhibitors similar to a face-to-face encounter. As participant you can access the VirtualExpo HERE. Upon entering you will see an exhibition overview and be able to select which booth you want to pay a visit to. In the exhibition overview the companies will mark when they are available “now live” / or “visit anytime”.  

Exhibitor Quiz

And of course we will feature our challenging Exhibitor Quiz. At each of the 12 Life Science Tuesdays we will run an extra quiz – so you have 12 opportunities to win! The objective is to visit many booths and answer the questions correctly at a given Life Science Tuesday!

     

Tools & Interactivity

We will be using the following tools and platforms for conducting and promoting the online meeting:

  • Zoom: virtual meeting with plenary room and breakout rooms 
    IMPORTANT: The Zoom invitation details have been sent to participants via e-mail (17. Sept. 2020). The information on how to join is also available by logging in to the registration system

INTERACTIVITY in our virtual meeting room is of utmost importance for us. With Zoom we have a tool where we can have all participants in a plenary room and can create ample breakouts to mix/meet/discuss. And we are very flexible – if, in the course of a topic, a group needs a breakout room for further discussion, we can facilitate that ad-hoc.

  • ÖGMBT Webpage with integrated Conference Management System and VirtualExpo platform
  • Social Media Channels: YouTube / Facebook / LinkedIn

Congress Office

Austrian Association of Molecular Life Sciences and Biotechnology (ÖGMBT)
Marxbox, VBC
Helmut-Qualtinger-Gasse 2,
Stiege 02, EG L.01
T: +43676/3611986
E: This email address is being protected from spambots. You need JavaScript enabled to view it.

If you have any queries related to the Annual Meeting please write an email to This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Eva Binder, Erber AG, Getzersdorf, AT

Eva Binder

Eva Binder studied technical Chemistry at the Technical University Vienna, wíth a PhD in Biochemistry and Biotechnology. She also holds a Master in Knowledge-Management. 1996 she became Director of Strategic Research at BIOMIN, 2003 she was promoted to Chief Scientific Officer for BIOMIN und ROMER LABS and moved to Singapore for two years, where she was responsible for the implementation of R&D process-management-tools and QA. 2011 she became VP R&D in the Erber AG, since 2018 she was also Managing Director of ERBER Future Business (EFB), the incubator of ERBER Group. Since May 1, 2019 she is Director of Executive Board, Research & Development and Innovation.

Doryen Bubeck, Imperial College London, GB

Doryen Bubeck

Doryen Bubeck received her PhD in Biophysics from Harvard University in 2005 where she used cryo-electron microscopy to investigate the cell entry mechanism of poliovirus.  As an EMBO postdoctoral fellow and Cancer Research Institute Fellow at the University of Oxford, she continued to explore the structures of membrane proteins, focusing on the complement immune pathway. Doryen Bubeck is a Senior Lecturer in Structural Biology within the Department of Life Sciences and recipient of a European Research Council Consolidator Award.  Her current research adopts an integrated structural approach merging cryo-electron microscopy and Xray crystallography to investigate the role of membrane proteins in host-pathogen interactions. She aims to investigate how membrane attack complex (MAC) pore formation is controlled, a process important for fighting infections and preventing complement-mediated tissue damage.

Teresa Carlomagno, Leibniz University Hannover, DE

Teresa Carlomagno

Our group investigates the functional mechanisms of molecular machines and their regulation by small molecules inhibitors, with a special focus on RNA processing and regulation. We develop complementary structure biology approaches to access the structure of large multi-components complexes in solution

Bertram Daum, University of Exeter, GB

Bertram Daum

I did my PhD in the group of Werner Kühlbrandt at the MPI of Biophysics in Frankfurt.

After a postdoc in the same lab, I took up an independent PI position at the Living Systems Institute at the University of Exeter, UK. My research focuses on elucidating the structure and function of molecular machines and cell surface proteins across domains by cryoEM. 

Mark Dürkop, BOKU, AT

Mark Dürkop

With more than 10 years of experience, Mark is a passionate expert in the field of biopharmaceutical process development. He worked together with several Top25 Pharma companies in different projects targeting their needs in process development and understanding.

Within the last months, he was together with Miriam Klausberger responsible at BOKU to set up a strong consortium to develop, evaluate and commercialize COVID19 antigens produced at BOKU. Together with several universities and companies, this huge mission was efficiently set into place. This success story will be presented on day 1 in the plenary session. 

Besides the COVID19 initiative, Mark is a co-founder and the CEO of Novasign GmbH. The company supports biopharma customers to speed up the development process of NBE and biosimilars to not only reduce the development costs but also to bring these molecules faster into the clinical trials and ultimately to the market.  

Hesso Farhan, University of Oslo, NO

Hesso Farhan

I am originally from Vienna, where I did my doctoral thesis. After a postdoctoral stay in the labs of Hans-Peter Hauri and Dirk Bumann in Basel (Switzerland), I started my junior group in 2011 at the Biotechnology Institute Thurgau at the University of Konstanz. In 2016, I accepted a professorship at the University of Oslo (Norway) and will by the end 2020 move to Innsbruck where I will be heading the Institute of Pathophysiology.

 

Christian Gruber, Innophore GmbH, AT

Christian Gruber

I graduated in biochemistry at the University of Graz, Austria, where I completed my Ph.D. in bioorganic chemistry and structural biology. During my studies I moved to the Royal Institute of Technology in Stockholm, Sweden. Afterwards, I continued as a postdoctoral researcher at the Institute of Molecular Biosciences in Graz, Austria, before moving to the Excellence cluster „Simulation Technology“ at the University of Stuttgart, Germany. Currently I am a senior scientist at the Austrian Centre of Industrial Biotechnology in the field of Protein Design & Engineering. In 2016 we founded Innophore, a biotech Start-Up employing the Catalophore Enzyme & Drug Discovery technology. My current research interests as a scientist and CEO of Innophore are focused on enzymology and the study of structural, kinetic, and thermodynamic properties of enzyme reactivity and inhibition by means of computational methods and structural biology.

David Haselbach, IMP, AT

David Haselbach

David Haselbach is a biophysicist using cryo EM to study molecular machines of the Ubiquitin Proteasomes system. After a PhD and Postdoc in the lab of Holger Stark where he learned the inner workings of the electron microscope, he started his own lab at the IMP in Vienna in 2017.

Christof R. Hauck, Universität Konstanz, DE

Christof R. Hauck

Christof Hauck has studied Biology at the University of Heidelberg and completed his PhD at the University of Tübingen. Following a postdoctoral stay at The Scripps Research Institute in La Jolla, CA, he has been an independent group leader at the Research Center for Infectious Diseases at the University of Würzburg. Since 2006 he is Full Professor for Cell Biology at the Department of Biology at the University of Konstanz, Germany.

Brian Kennedy, National University Singapore, SG

Brian Kennedy

Dr. Brian Kennedy is internationally recognized for his research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of delaying, detecting, and preventing human aging and associated diseases. He is a Professor in the Departments of Biochemistry and Physiology at National University Singapore and Director of the Centre for Healthy Ageing in the National University Health System. From 2010 to 2016 he was the President and CEO of the Buck Institute for Research on Aging. Currently he remains as a Professor at the Institute. Dr. Kennedy also has an adjunct appointment at the USC Davis School of Gerontology. Dr. Kennedy is also actively involved Biotechnology companies, serving in consulting and Board capacities, as well as Scientific Director of Affirmativ Health. Dr. Kennedy also serves as a Co-Editor-In-Chief at Aging Cell.

Marcus Koeller, Klinik Favoriten, AT

Marcus Koeller

Prof. Marcus Köller, MD; Specialist in Internal Medicine, Rheumatology and Geriatrics; Head of the Dept. for Acute Geriatric Care - Klinikum Favoriten - Vienna. President of the Austrian Society of  Geriatrics and Gerontology.

 

Ondrej Kuda, Institute of Physiology, Czech Academy of Sciences, CZ

Ondrej Kuda

My research is focused on bioactive lipids, namely eicosanoids, docosanoids, endocannabinoids, and branched fatty acid esters of hydroxy fatty acids (FAHFAs). I am interested in the metabolism and metabolic pathways related to obesity, type 2 diabetes, and nutrition in mice and men, and also in the lipidomics, fluxomics and bioinformatics.

Cristina Mayor-Ruiz, CeMM, AT

Cristina Mayor-Ruiz

Cristina Mayor-Ruiz obtained her PhD under the supervision of Óscar Fernández-Capetillo at the CNIO (Madrid) in 2017, exploring mechanisms of resistance to genotoxic and targeted anticancer therapies. In 2018, she joined the group of Georg Winter at CeMM (Vienna) supported by EMBO and Marie Curie postdoctoral fellowships. Her research interests have focused on different aspects of targeted protein degradation: cellular effectors, resistance mechanisms, drug screens, identification of new molecular glues, etc. In addition, she has developed chemical-biology approaches to identify and disrupt the transcriptional effectors of mutant RAS proteins. She will start her own group at IRB Barcelona at the end of 2020, where she plans to explore the multifaceted subtleties of targeted protein degradation to ultimately control protein activity in cancer.

Marlene Oeffinger, Institut de recherches cliniques de Montréal (IRCM), CA

Marlene Oeffinger

Marlene Oeffinger studied Biology at the University of Vienna, carried out her Master’s Project at University College London with Alan Hall, and her Ph.D. at the University of Edinburgh with David Tollervey, where she began to investigate ribosomal RNA maturation and ribonucleoprotein complexes. After a postdoc with Mike Rout at Rockefeller University, she established her group at the Institut de recherches cliniques Montréal (IRCM), which focuses on understanding the dynamic interactions and regulation along various RNA maturation pathways that lead to RNP heterogeneity and functional specialization. Using proteomic, RNomic, biochemical, and computational approaches in S. cerevisiae, zebrafish, and human cells her work seeks to elucidate the differential establishment and regulation of RNA maturation pathways and their links to DNA damage networks and neurodegenerative disease development, specifically amyotrophic lateral sclerosis (ALS).

Jillian Petersen, University of Vienna, AT

Jillian Petersen

Jillian is Associate Professor at the Center for Microbiology and Environmental Systems Science, University of Vienna. Following undergraduate studies in her native Australia, she studied and researched marine microbiology at the Max Planck Institute in Bremen, Germany. She won a Vienna Research Group grant from the Vienna Science and Technology Fund, which brought her to Austria in 2015.

Karin Schaupp, Intern. Innovation and Business Consulting, Kainbach bei Graz, AT

Karin Schaupp

Karin Schaupp studied Pharmaceutical Chemistry and received her doctorate at the Karl-Franzens University in Graz. 23 years of industrial experience from department head to member of the board of Fresenius Kabi AG with worldwide business responsibility. Since 2003, self-employed consultant at the interface between science and business with a focus on innovation and corporate development.

Karin Schindler, Federal Ministry Republic of Austria - Social Affairs, Health, Care and Consumer Protection, AT

Karin Schindler

Dr Schindler works in the Austrian Federal Ministry of Social Affairs, Health, Health Care and Consumer Protection. She is head of the division which deals with issues related to mother, child, adolescent and gender health and nutrition. She has worked as a researcher at the Medical University of Vienna for more than 15 years. Her main research interests were nutrition in the context of disease, including obesity, diabetes, disease and age-related malnutrition. She co-founded nutritionDay worldwide, a project to increase awareness of disease and age-related malnutrition in hospitals and nursing homes. Dr Schindler has worked at WHO/Europe in the update oft he Food and Nutrition Action Plan and to prepare for the Vienna conference. She is a nutrition scientist trained at the University of Vienna. She qualified as a Privatdozent at the Medical University Vienna.

Joachim Seipelt, Nuvonis Technologies, AT

Joachim Seipelt

Joachim Seipelt holds a PhD in biochemistry, gained industrial experience at Boehringer Ingelheim and academic experience at the Medical University Vienna as an independent group leader. He was co-founder of AVIR Green Hills Biotechnology from 2002-2012, where he was in charge of third party funded projects and business development. Dr. Seipelt was project manager for several European Commission projects with a grant volume of € 13,2 Mio, involving 12 partner institutions across Europe. On the business development side, Dr. Seipelt was involved in licensing activities that resulted in the formation of a spin-off company and several license agreements with major pharmaceutical companies. From 2013-2017 he was Head of a Business Unit at the Austria Wirtschaftsservice GmbH (aws), Austria’s funding bank. He was responsible for programs that support startup companies and creative industries with an annual budget of € 35 Mio. and a headcount of 53. Currently, he is COO of Nuvonis Technologies in Vienna and COO of BlueSky Immunotherapies in Vienna, a clinical stage biotech company that is developing immunotherapies against cancer.

Stephan Sieber, Technical University of Munich, DE

Stephan Sieber

Stephan A. Sieber studied chemistry at the universities of Marburg, Germany and Birmingham, England. He did his graduate studies in the labs of Prof. Marahiel, University of Marburg and Prof. Christopher T. Walsh at Harvard Medical School, Boston, USA. Soon after his graduation he joined the group of Prof. Benjamin F. Cravatt for his postdoctoral work. In 2006 he started his independent research career at the University of Munich (LMU), Germany, funded by a DFG Emmy-Noether grant. In 2009 he was appointed full professor at Technische Universität Munich and received an ERC starting as well as consolidator grant. His research focus is in the field of chemical biology and chemical proteomics with emphasis on the reactivity of natural products and their dedicated targets in prokaryotic as well as eukaryotic cells.

Major achievements include the investigation of new treatment options for bacterial infections. These studies are of major importance since the evolution of multidrug resistant bacterial pathogens poses a serious threat to public health.

 

Andreas Simm, Martin-Luther-Universität Halle-Wittenberg, DE

Andreas Simm

Prof. Dr. Andreas Simm (PhD) studied biology and got his venia legendi in Physiological Chemistry. His research is concentrated on a) protein glycation as a basic mechanism on ageing, b) cardiovascular ageing, and c) biomarkers of ageing. He is Professor for Molecular Cardiovascular Surgery, the Director of the Centre for Medical Basic Research (ZMG), the Director of the Interdisciplinary Centre on Ageing Halle (IZAH) and since September this year President of the German Society for Gerontology and Geriatrics (DGGG).

Carlos Oscar Sorzano, CSIC, ES

Carlos Oscar Sorzano

Carlos Oscar S. Sorzano is an Electrical Eng., Computer Scientist and Mathematician working in Cryo-Electron Microscopy for more than 20 years. He is co-director of the Instruct Image Processing Center together with Dr. Carazo. Their group are the main developers of Xmipp and Scipion.

Jordan Turnbull, ViraTherapeutics, AT

Jordan Turnbull

Jordan Turnbull studied Biomedicine at UCL (University College London) and proceeded there as Engeneering Doctoral Researcher for 5 years. His next career steps were as PostDoc in Ulm & Vienna, where he continued his work in Viral Vector Downstreaming Processing. Since Nov 2019 he is a principal scientist for Viratherapeutics, focussing on Oncolytic Viral Vector Downstreaming.

Oliver Stegle, German Cancer Research Center, DE

Oliver Stegle

Dr. Stegle earned his PhD from the University of Cambridge in Physics in 2009 and worked as postdoc at the Max Planck Institute for Intelligent Systems in Tübingen from 2009 to 2012. He has been a group leader at the EMBL European Bioinformatics Institute since 2012 before moving to Heidelberg in 2018 where he heads a division at the German Cancer Research Center and is group leader at the European Molecular Biology Laboratory. He has received several recognitions, coordinates the ELLIS Health program and is an ERC investigator.

Daniela S. Thommen, Netherlands Cancer Institute, NL

Daniela S. Thommen

Daniela Thommen is a Junior Group Leader at the Netherlands Cancer Institute. She received her MD and PhD from the University of Basel, Switzerland. She then specialized in Medical Oncology in Switzerland. In parallel to her clinical training, she worked as a research fellow in tumor immunology at the Department of Biomedicine in Basel. In 2016, she joined the lab of Prof. Ton Schumacher at the Netherlands Cancer Institute, and started her own lab as a Junior group leader in 2020. Her research focuses on understanding the role of intratumoral immune cell heterogeneity for immunotherapy response and on the development of novel biomarkers and personalized immunotherapy strategies using patient-derived organotypic models. Daniela Thommen is the recipient of the 2019 Swiss Pfizer Research Prize in Oncology.

Heike Walles, Otto-von-Guericke-University Magdeburg (OvGU), DE

Heike Walles

From 2014 to 2018, Prof. Dr. rer. biol hum. Heike Walles set up the Fraunhofer Translation Center “Regenerative Therapies” in Würzburg with a focus on 3D human tissue models for the preclinical development of pharmaceuticals.

This knowledge is now transferred to the new product class “medical devices". Therefore Prof. Heike Walles is establishing a Core Facility Tissue Engineering (CF TE) at Otto-von-Guericke- University (OVGU) Magdeburg since 2019. In this CF TE, the focus is the up scaling and standardization of human 3D tissue models for preclinical studies to CE-mark medicinal products according the new medical device regulation (MDR).

Saurabh Gautam, ViraTherapeutics GmbH (Boehringer Ingelheim), AT

Saurabh Gautam

Dr. Saurabh Saurabh currently works as a principal scientist in the bioprocess innovation unit at ViraTherepeutics GmbH, a Boehringer Ingelheim group of companies. He has previously worked at Max Planck Institute of Biochemistry (Munich region, Germany) and obtained his Ph.D. from Indian Institute of Technology Delhi (India) in macromolecular assemblies.

Christian Gruber, Innophore GmbH, AT

Christian Gruber

I graduated in biochemistry at the University of Graz, Austria, where I completed my Ph.D. in bioorganic chemistry and structural biology. During my studies I moved to the Royal Institute of Technology in Stockholm, Sweden. Afterwards, I continued as a postdoctoral researcher at the Institute of Molecular Biosciences in Graz, Austria, before moving to the Excellence cluster „Simulation Technology“ at the University of Stuttgart, Germany. Currently I am a senior scientist at the Austrian Centre of Industrial Biotechnology in the field of Protein Design & Engineering. In 2016 we founded Innophore, a biotech Start-Up employing the Catalophore Enzyme & Drug Discovery technology. My current research interests as a scientist and CEO of Innophore are focused on enzymology and the study of structural, kinetic, and thermodynamic properties of enzyme reactivity and inhibition by means of computational methods and structural biology.

Sponsors & Exhibitors

  • Abberior 440x252

  • Springer 440x252

  • THP logo rgb 300 1changed

  • 1 pol

  • BruLogo RGB

  • logo mp bleu HQ CMJNtrans

     

     

     

  • agilent

  • NEB GmbH with inspired claim square 4c 4

  • SzSc Logo 4C kompakt 10cm150dpi

  • Takara 440x252

  • Logo greiner bioone 2c RGB dcf2d90b f755 4fa2 b7f0 6293b149abd7

  • biomedica 110x63

  • Lexogen Logo plus Claim

  • METROHM INULA resized

  • Biozym110x63

  • 02 MIC Logo Austria OrangeGrey RGB 440x252

  • eurofins110

  • FEMS19_acronym112x65.jpg

  • ÖGMBT Twist Logo 440x242px

  • 10x320.jpg

  • OROBOROS kein weißer hintergrund 1

  • Beckman Coulter Logo resized

  • Universtität Graz resized

  • CCAS External banner urgent 440x242 P1

  • FEBS logo resized

  • Hookipa Pharma Logo weiß

  • LBG Career Center Logo 2020 small wide

  • csm lohmann rauscher logo resized

  • msd resized

  • phoenestra resized

  • Ribbon Biolabs Logotype RGB Blue Red resized

  • takeda 440x252 logo

  • TILL spermidineLIFE resized

next prev